Abstract
This brief report focuses on the evaluation and diagnosis of clinically localized renal masses in children and adults with Von Hippel–Lindau (VHL) disease. Counseling considerations pertinent to the urologists, medical oncologists, and multidisciplinary teams involved in the care of these patients are addressed. As practice patterns regarding the evaluation and management of VHL tumors can vary considerably, this report aims to provide guidance on some of the controversies associated with the diagnostic evaluation and initial management of localized renal masses in VHL patients.
Similar content being viewed by others
References
Linehan WM, Lerman MI, Zbar B (1995) Identification of the von Hippel–Lindau (VHL) gene: its role in renal cancer. JAMA J Am Med Assoc 273(7):564–570. https://doi.org/10.1001/jama.1995.03520310062031
Maher ER, Neumann HPH, Richard S (2011) von Hippel–Lindau disease: a clinical and scientific review. Eur J Hum Genet 19(6):617–623. https://doi.org/10.1038/ejhg.2010.175
Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS (2017) A review of von Hippel–Lindau syndrome. J Kidney Cancer VHL 4(3):20. https://doi.org/10.15586/jkcvhl.2017.88
Gossage L, Eisen T, Maher ER (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15(1):55–64. https://doi.org/10.1038/nrc3844
Binderup MLM, Jensen AM, Budtz-Jørgensen E, Bisgaard ML (2017) Survival and causes of death in patients with von Hippel–Lindau disease. J Med Genet 54(1):11–18. https://doi.org/10.1136/jmedgenet-2016-104058
Ashouri K, Mohseni S, Tourtelot J, Sharma P, Spiess PE (2015) Implications of von Hippel–Lindau syndrome and renal cell carcinoma. J Kidney Cancer VHL 2(4):163. https://doi.org/10.15586/jkcvhl.2015.41
Rednam SP, Erez A, Druker H et al (2017) von Hippel–Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23(12):e68–e75. https://doi.org/10.1158/1078-0432.CCR-17-0547
Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B (1995) von Hippel–Lindau disease: genetic, clinical, and imaging features. Radiology 194(3):629–642. https://doi.org/10.1148/radiology.194.3.7862955
Maher ER (2018) Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol 36(12):1891–1898. https://doi.org/10.1007/s00345-018-2288-5
Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel–Lindau disease. Q J Med 77(283):1151–1163. https://www.ncbi.nlm.nih.gov/pubmed/2274658. Accessed 27 Aug 2019
Hes FJ, van der Luijt RB, Lips CJ (2001) Clinical management of von Hippel–Lindau (VHL) disease. Neth J Med 59(5):225–234. https://www.ncbi.nlm.nih.gov/pubmed/11705642. Accessed 27 Aug 2019
Nielsen SM, Rhodes L, Blanco I et al (2016) von Hippel–Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol 34(18):2172–2181. https://doi.org/10.1200/JCO.2015.65.6140
Lonser RR, Glenn GM, Walther M et al (2003) von Hippel–Lindau disease. Lancet (London, England) 361(9374):2059–2067. https://doi.org/10.1016/S0140-6736(03)13643-4
HL family alliance: the VHL handbook: what you need to know about VHL: a reference handbook for people with von Hippel–Lindau disease, their families, and support personnel. Boston, MA 2014 VHL Family Alliance. No Title
Balshem H, Helfand M, Schünemann HJ et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 64(4):401–406. https://doi.org/10.1016/j.jclinepi.2010.07.015
Lonser RR, Glenn GM, Walther M et al (2003) von Hippel–Lindau disease. Lancet, vol 361. Elsevier Limited, Amsterdam, pp 2059–2067. https://doi.org/10.1016/S0140-6736(03)13643-4
Binderup ML, Bisgaard ML, Harbud V et al (2013) von Hippel–Lindau disease (vHL): national clinical guideline for diagnosis and surveillance in Denmark. Dan Med J 60(12):B4763. https://www.embase.com/search/results?subaction=viewrecord&from=export&id=L370377660. Accessed 27 Aug 2019
Kruizinga RC, Sluiter WJ, de Vries EGE et al (2014) Calculating optimal surveillance for detection of von Hippel–Lindau-related manifestations. Endocr Relat Cancer 21(1):63–71
(2018) ACR manual on contrast media version 10.3, 2018, pp 81–87
Thompson RH, Hill JR, Babayev Y et al (2009) Metastatic renal cell carcinoma risk according to tumor size. J Urol 182(1):41–45. https://doi.org/10.1016/j.juro.2009.02.128
Smaldone MC, Kutikov A, Egleston BL et al (2012) Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 118(4):997–1006. https://doi.org/10.1002/cncr.26369
Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DYT, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431. https://doi.org/10.1016/S0022-5347(05)00148-5
Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma—a meta-analysis and review. J Urol 179(4):1227–1234. https://doi.org/10.1016/j.juro.2007.11.047
Jewett MAS, Mattar K, Basiuk J et al (2011) Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 60(1):39–44. https://doi.org/10.1016/j.eururo.2011.03.030
Park SW, Lee SS, Lee DH, Nam JK, Chung MK (2017) Growth kinetics of small renal mass: initial analysis of active surveillance registry. Investig Clin Urol 58(6):429–433. https://doi.org/10.4111/icu.2017.58.6.429
Mason RJ, Abdolell M, Trottier G et al (2011) Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 59(5):863–867. https://doi.org/10.1016/j.eururo.2011.02.023
Pierorazio PM, Johnson MH, Ball MW et al (2015) Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM Registry. Eur Urol 68(3):408–415. https://doi.org/10.1016/j.eururo.2015.02.001
Jilg CA, Neumann HP, Gläsker S et al (2012) Growth kinetics in von Hippel–Lindau-associated renal cell carcinoma. Urol Int 88(1):71–78. https://doi.org/10.1159/000333348
Schuhmacher P, Kim E, Hahn F et al (2019) Growth characteristics and therapeutic decision markers in von Hippel–Lindau disease patients with renal cell carcinoma. Orphanet J Rare Dis 14(1):235. https://doi.org/10.1186/s13023-019-1206-2
Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DYT, Uzzo RG (2009) Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115(13):2844–2852. https://doi.org/10.1002/cncr.24338
Pomerri F, Opocher G, Bosco CD, Muzzio PC, Gennaro G (2015) Optimal follow-up intervals in active surveillance of renal masses in patients with von Hippel–Lindau disease. Eur Radiol 25(7):2025–2032. https://doi.org/10.1007/s00330-015-3591-9
Zhang J, Pan JH, Dong BJ, Xue W, Liu DM, Huang YR (2012) Active surveillance of renal masses in von Hippel–Lindau disease: growth rates and clinical outcome over a median follow-up period of 56 months. Fam Cancer 11(2):209–214. https://doi.org/10.1007/s10689-011-9503-5
Volpe A, Finelli A, Gill IS et al (2012) Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 62(3):491–504. https://doi.org/10.1016/j.eururo.2012.05.009
Burruni R, Lhermitte B, Cerantola Y et al (2016) The role of renal biopsy in small renal masses. Can Urol Assoc J 10(1–2):E28–E33. https://doi.org/10.5489/cuaj.3417
Marconi L, Dabestani S, Lam TB et al (2016) Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 69(4):660–673. https://doi.org/10.1016/j.eururo.2015.07.072
Hes FJ, Höppener JW, Luijt RB, Lips CJ (2005) Von hippel-lindau disease. Hered Cancer Clin Pract 3(4):171–178. https://doi.org/10.1186/1897-4287-3-4-171
Funding
This work was supported in part by the National Eye Institute Grant NIH/NEI 5K08EY027464-02 for ABD.
Author information
Authors and Affiliations
Consortia
Contributions
Protocol/project development: All authors. Data evaluation: All authors. Manuscript writing/editing: All authors.
Corresponding author
Ethics declarations
Conflict of interest
Kimryn Rathmell receives clinical research funding from Peloton. All other authors have no relevant conflict to disclose.
Research involving human participants and/or animals
Not needed.
Informed consent
Not needed.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chahoud, J., McGettigan, M., Parikh, N. et al. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World J Urol 39, 2409–2415 (2021). https://doi.org/10.1007/s00345-020-03441-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-020-03441-3